Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

In this study (n=466), addition of daratumumab to carfilzomib and dexamethasone was associated with prolonged progression-free survival (after median follow-up of 17 months, median not reached vs 15.8 months with carfilzomib and dexamethasone; HR 0.63; 95% CI 0.46-0.85; p=0.0027)

SPS commentary:

A related comment notes that this study focused mainly on fit and younger patients (only 11% above 74 years of age, 95% with ECOG performance score of 0-1), and the results are therefore only applicable to a similar myeloma population. Considering the higher frequency of treatment-related fatal adverse events (most caused by infections), administration of carfilzomib, dexamethasone and daratumumab to more vulnerable patients requires careful monitoring.


The Lancet

Resource links: